Title for MeetingAbstracts
Alphabetical listing of titles
-
R&D on new preventive medicine for the era of living with AIDS.
-
R-113281 (a Combined Tachykinin Receptor Antagonist) Potently Inhibits HIV-1 Infection of Human Blood Mononuclear Phagocytes.
-
R-115685, a Novel Parenteral Carbapenem: In Vitro Antibacterial Activity.
-
R-115685, A Novel Parenteral Carbapenem: In Vivo Antibacterial Activity.
-
R-115685, A Novel Parenteral Carbapenem: Mode of Action and Resistance Mechanisms.
-
R-115685, A Novel Parenteral Carbapenem: Pharmacokinetics and Metabolism in Laboratory Animals.
-
R-115685, A Novel Parenteral Carbapenem: Preclinical Safety Studies.
-
R-115685, a Novel Parenteral Carbapenem: Synthesis and Structure-Activity Relationships.
-
R-118958, a Unique Anti-Influenza Agent: a Prodrug Form of R-125489, a Novel Inhibitor of Influenza Virus Neuraminidase.
-
R-118958, a Unique Anti-Influenza Agent: Microscopic Examination of Drug Distribution in Lung after Intranasal Administration to Mice.
-
R-118958, a Unique Anti-Influenza Agent: Pharmacokinetics and Metabolism after Intranasal/Intratracheal Administration to Rats and Mice.
-
R-118958, a Unique Anti-Influenza Agent: Preclinical Safety Studies.
-
R-118958, a Unique Anti-Influenza Agent: Safety, Tolerability and Pharmacokinetics (PK) in Healthy Male Volunteers.
-
R-118958, a Unique Anti-Influenza Agent: Single Administration Shows High Efficacy for Both Prophylaxis and Treatment.
-
R-120758, A Novel Triazole Antifungal Agent: In Vitro Antifungal Activity.
-
R-120758, A Novel Triazole Antifungal Agent: In Vivo Antifungal Activity.
-
R-120758, A Novel Triazole Antifungal Agent: Pharmacokinetics and Metabolism in Laboratory Animals.
-
R-120758, A Novel Triazole Antifungal Agent: Preclinical Safety Studies.
-
R-120758, A Novel Triazole Antifungal Agent: Synthesis and Structure-Activity Relationships.
-
R-HU erythropoietin (EPO) in HIV/zidovudine (ZDV) associated anemia.
-
R-R variations of the heart rate during the gravity transition produced by parabolic flight.
-
R165335-TMC125, A Novel Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) with nanoMolar Activity against NNRTI Resistant HIV Strains.
-
R165335-TMC125, A Third Generation Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Inhibits 98% of More Than 2,000 Recombinant HIV Clinical Isolates at 100nM.
-
R170591, a Novel Fusion Inhibitor with picoMolar Activity against Respiratory Syncytial Virus (RSV).
-
R5 but not X4 HIV strains kill primary CD4+ T cells through the fas signaling pathway.
-
R5 but Not X4 Primary Viral Isolates of HIV-1 Can Localize Their cDNA to the Nucleus in Monocyte Derived Macrophages.
-
R5 HIV Infection of Langerhans Cells within Epithelial Tissue Explants Is Regulated by Compound CCR5 Polymorphisms and Is Blocked by Chemically Modified RANTES Analogues B.
-
R5 HIV-1 INFECTION OF FOETAL THYMIC ORGAN CULTURE INDUCES CYTOKINE AND CCR5 EXPRESSION: COMPONENTS OF A PATHOGENIC PATHWAY.
-
R5 HIV-1 Patient Isolates are Pathogenic in Fetal Thymic Organ Culture.
-
R5 HIV-1 Strains Replicate More Efficiently in Primary CD4+ T Cell Cultures than X4 HIV-1 Strains.